DSG Partners With Biotech Company To Battle Progressive And Chronic Kidney Disease

Main Category: Urology / Nephrology
Also Included In: Clinical Trials / Drug Trials
Article Date: 03 Feb 2010 - 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


DSG's eCaseLink™ Electronic Data Capture (EDC) and data management are currently being used by a biotechnology company for two current phase 2 and phase 2a clinical trials for treatments of progressive and chronic kidney disease. The company uses DSG's eCaseLink™ to automate and manage the data collection process during the clinical trial lifecycle. In addition, DSG combines data management services with eCaseLink™ to seamlessly optimize data collection and analysis.

The result is clean clinical trial data, collected and analyzed efficiently. This accelerates the clinical trial process, helping to safely speed these treatments to those who need them.

The phase 2 study, is a new treatment that may help people in the early stage of diabetic nephropathy, a progressive kidney disease. The second study, currently in phase 2a, is a treatment for anemia in chronic kidney disease.

The two clinical trials demand a data capture and management solution that speeds time-to-market while complying with all appropriate regulatory procedures. eCaseLink™ EDC provides real-time, clean data, which facilitates quick data review, reporting and decision making for the company.

The eCaseLink™ system is a critical tool for the investigator site and monitoring personnel, in part because it greatly reduces the amount of time it takes to "lock" the clinical database. Database lock occurs once all data has been verified and cleaned through the data management process. Once "locked," the study's statistical analysis is performed and results are reported.

"Partnering with innovative drug companies like this, helping to find ways to help those suffering from progressive and chronic kidney disease, is an ideal way for DSG's unique eCaseLink™ EDC system to be employed in clinical trials," said Tony Varano, CEO of DSG.

Source
DSG Inc.

Article adapted by Medical News Today from original press release.
Visit our urology / nephrology section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
DSG Inc.. "DSG Partners With Biotech Company To Battle Progressive And Chronic Kidney Disease." Medical News Today. MediLexicon, Intl., 3 Feb. 2010. Web.
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/177957.php>

APA
DSG Inc.. (2010, February 3). "DSG Partners With Biotech Company To Battle Progressive And Chronic Kidney Disease." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/177957.php.

Please note: If no author information is provided, the source is cited instead.


Urology / Nephrology

Most Popular Articles



Follow Our Urology News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Urology / Nephrology Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »